NEWS RELEASE

Now ideas for wellness

meiji

Meiji Seika Pharma Co., Ltd.

20 October 2021

Meiji Seika Pharma Announces the Launch of Hiyasta® Tablets 10mg, an Anti-Malignant Tumor Agent

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi) today announced the launch of Hiyasta® Tablets 10mg (generic name: tucidinostat), an anti-malignant tumor agent for treatment of relapsed and refractory adult T-cell leukemia-lymphoma (ATLL), in Japan.

Hiyasta® Tables is an orally available epigenetic immunomodulator licensed from HUYA Bioscience International, LLC* (Headquarters: San Diego, California, United States, CEO and Executive Chair: Dr. Mireille Gillings), and its subsidiary Huya Japan G.K. obtained the manufacturing and marketing approval in Japan on June 23th, 2021. Hiyasta Tablets has been granted an orphan drug designation for relapsed and refractory ATLL by the Ministry of Health, Labour and Welfare.

Meiji Seika Pharma strives to promote proper use and provide information of Hiyasta® Tablets so that it can be applied as a new treatment option for ATLL and contribute to improving the QOL and prognosis of the patients.

*: For further information, please visit the website at: https://huyabio.com/

Product Outline of “Hiyasta® Tablets 10mg”

Brand name	Hiyasta® Tablets 10mg
Generic name	tucidinostat
Indications	Relapsed and refractory adult T-cell leukemia-lymphoma
Use & Dosage	Usually, for adults, 40mg of tucidinostat should be orally administrated after a meal twice a week with 3- or 4-day interval. The dose may be decreased according to the symptom.
Date of manufacturing and marketing approval	June 23, 2021
Date listed in NHI reimbursement price listing	August 12, 2021
Date of initial marketing in Japan	October 20, 2021
NHI reimbursement price	20,030.50 JPY/tablet
Packaging	PTP packaging: 8 tablets（8 tablets × 1 sheet）
Manufacturing distributor	Huya Japan G.K.
Sales agent	Meiji Seika Pharma Co., Ltd.

*For further information, please refer to the package insert.